본문으로 건너뛰기
← 뒤로

Core Decompression for Osteonecrosis of the Femoral Head in Pediatric Hematologic Malignancy Survivors: A Systematic Review.

메타분석 1/5 보강
Journal of surgical orthopaedic advances 2026 Vol.35(1) p. 10-13
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
환자: a history of hematologic malignancy who developed ONFH
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Level of Evidence: Level III, Diagnostic study. (Journal of Surgical Orthopaedic Advances 35(1):010-013, 2026).

Krisanda EK, Morris CD, Levin AS

📝 환자 설명용 한 줄

Children treated for leukemia or lymphoma are predisposed to a higher incidence of osteonecrosis at a young age.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 연구 설계 systematic review

이 논문을 인용하기

↓ .bib ↓ .ris
APA Krisanda EK, Morris CD, Levin AS (2026). Core Decompression for Osteonecrosis of the Femoral Head in Pediatric Hematologic Malignancy Survivors: A Systematic Review.. Journal of surgical orthopaedic advances, 35(1), 10-13.
MLA Krisanda EK, et al.. "Core Decompression for Osteonecrosis of the Femoral Head in Pediatric Hematologic Malignancy Survivors: A Systematic Review.." Journal of surgical orthopaedic advances, vol. 35, no. 1, 2026, pp. 10-13.
PMID 41811254 ↗

Abstract

Children treated for leukemia or lymphoma are predisposed to a higher incidence of osteonecrosis at a young age. Core decompression (CD) is performed for treatment of osteonecrosis of the femoral head (ONFH) to delay or prevent subchondral collapse and subsequent total hip arthroplasty (THA). The goal of the present systematic review was to determine outcomes of CD in pediatric patients with a history of hematologic malignancy who developed ONFH. Of 4,424 studies screened by title, abstract, and full text, 4 retrospective studies were included. Of 253 hips with ONFH, CD was performed in 78 (30.8%). Conversion to THA occurred in 46.2% of patients an average of 20.3 months after CD. None of the studies reported a significant difference in risk of joint collapse following CD. There is limited evidence for or against the use of CD in the treatment of ONFH for pediatric patients with a history of hematologic malignancy. Level of Evidence: Level III, Diagnostic study. (Journal of Surgical Orthopaedic Advances 35(1):010-013, 2026).

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반